Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Multiple Sclerosis Drugs - Niger

Niger
  • The projected revenue for the Multiple Sclerosis Drugs market in Niger is estimated to reach US$2.04m in 2024.
  • It is expected that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 2.39%, leading to a market volume of US$2.29m by 2029.
  • When compared globally, United States is anticipated to generate the highest revenue of US$11.77bn in 2024.
  • Niger's limited access to healthcare infrastructure hinders the availability and affordability of multiple sclerosis drugs in the country.

Definition:
This market covers drugs to treat the neurological autoimmune disease multiple sclerosis. As there is no cure for multiple sclerosis, the goal is to improve functions after an attack or to prevent attacks. Different types of medication include immunomodulators, immunosuppressants, and interferons. Monoclonal antibodies are now being increasingly used.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Biogen, Roche, Novartis, Sanofi

In-Scope

  • Drugs to treat multiple sclerosis
  • Monoclonal antibodies
  • Immunosuppressants

Out-Of-Scope

  • Monoclonal antibodies and immunosuppressants for the treatment of other diseases
  • Treatment of other autoimmune diseases
  • Alternative medicine
Multiple Sclerosis Drugs: market data & analysis - Cover

Market Insights report

Multiple Sclerosis Drugs: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Most recent update: Mar 2024

    Source: Statista Market Insights

    Analyst Opinion

    The Multiple Sclerosis Drugs market in Niger has seen some interesting trends and developments in recent years.

    Customer preferences:
    There is a growing demand for Multiple Sclerosis Drugs in Niger due to the increasing prevalence of the disease in the country. Patients are seeking effective treatments that can help manage their symptoms and improve their quality of life. As a result, there is a strong demand for drugs that are proven to be effective in treating the disease.

    Trends in the market:
    One of the key trends in the Multiple Sclerosis Drugs market in Niger is the increasing availability of generic drugs. This has helped to bring down the cost of treatment and make it more accessible to patients who may not be able to afford the high cost of branded drugs. In addition, there is a growing trend towards personalized medicine, with doctors and patients seeking treatments that are tailored to their specific needs.

    Local special circumstances:
    Niger is a low-income country with a relatively small healthcare market. This presents a number of challenges for companies operating in the Multiple Sclerosis Drugs market, including limited resources and a lack of infrastructure. However, there are also opportunities for companies that can provide affordable and effective treatments that meet the needs of the local population.

    Underlying macroeconomic factors:
    The Multiple Sclerosis Drugs market in Niger is influenced by a range of macroeconomic factors, including government policies, healthcare spending, and economic growth. The government has taken steps to improve healthcare access and affordability, but there is still a long way to go in terms of providing universal coverage. Economic growth has been slow in recent years, which has limited the resources available for healthcare investment. However, there are signs that the economy is starting to recover, which could lead to increased investment in healthcare in the future.

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Multiple Sclerosis Drugs: market data & analysis - BackgroundMultiple Sclerosis Drugs: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Global pharmaceutical industry - statistics & facts

    The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.